Who we are

Owen Mumford specialises in integrated design and build services from a broad range of self-injection platform devices for the pharmaceutical industry.

From the first automatic lancing device to our patented self-injection devices, with Owen Mumford you have access to unrivalled experience in designing, developing and delivering solutions to help you make adherence easier for patients.


With more than 65 years’ experience, your device is in trusted hands with Owen Mumford.

From day one, we will guide you throughout the development process; at every step, you will benefit from professional and supportive project management, processes, industrialisation and production for a smooth development and launch.

The springless, passive safety device for pre-filled syringes

Fully designed, developed and ready for commercial supply

Comfort

Large, ergonomic plunger head and a smooth, integrated finger flange, resulting in an integrated look and feel.

Secure plunger

Plunger cannot detach when removing the RNS.

Reduced risk

No compromise to sterility in assembly – plunger does not touch the bung.

User confidence

Syringe barrel is unobscured, allowing the user to check the contents of the syringe, and to confirm the full dose has been delivered.

Reliability

Prevention of occidental activation e.g. in transit.

Simple 2-step final sembly

Final assembly process is simple and outside of the sterile filling area.

Cost effective

Designed to work with standard, pre-filled syringes which means no change to existing primary container and minimises training costs.

Passive safety

Passive needle retraction means that the device is safe as soon as the plunger is fully depressed

Self-Injection Device Solutions 

Ensuring that patients are willing and able to inject their medication is key to their well-being. As pioneers in self-injection technologies, our experience enables us to effectively work with you to find the right drug delivery solution.


Please visit: omdevicesolutions.com

Go to article: Home | The deep dive for new drugsGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Hapa Company InsightGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Owen MumfordGo to article: The pharma industry briefingGo to article: Capsugel Company InsightGo to article: Swiss WorldCargoGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Underwater forests and the search for natures’ next drug treasure troveGo to article: Barc Lab Go to article: BEAGo to article: Developing drugs for NASH: the race to market Go to article: SmartCAE Company InsightGo to article: SmartCAEGo to article: Zulresso: the world’s first post-partum depression drugGo to article: EcocoolGo to article: Moehs Iberica SLGo to article: Predicting drug flops with AIGo to article: Abiogen PharmaGo to article: LaudaGo to article: Proteomics and the promise of ‘enriching’ clinical trials Go to article: Lubrizol Life SciencesGo to article: SkycellGo to article: EventsGo to article: TemptimeGo to article: Next issueGo to article: Pfanstiehl Company InsightGo to article: Pfanstiehl